Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. - Wikidata - wikimedia - TriplyDB

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

http://www.wikidata.org/entity/Q37991128

about

Antibody-drug conjugates as novel anti-cancer chemotherapeutics Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).Production of unique immunotoxin cancer therapeutics in algal chloroplasts Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Biochemical studies of the lagunamides, potent cytotoxic cyclic depsipeptides from the marine cyanobacterium Lyngbya majuscula.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Preparation and Antitumor Activity of CS5931, A Novel Polypeptide from Sea Squirt Ciona Savignyi Bouillonamide: a mixed polyketide-peptide cytotoxin from the marine cyanobacterium Moorea bouillonii.Immunoconjugates and long circulating systems: origins, current state of the art and future directions Industrial natural product chemistry for drug discovery and development.Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.Structural Diversity, Biological Properties and Applications of Natural Products from Cyanobacteria. A Review.Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.Tumor necrosis factor receptor 2 may promote the proliferation and drug resistance of Kapras299 and L428 lymphoma cells via the AKT and WNT/β-catenin signaling pathways.

P2860

Q26800175-5697368F-7FD7-4967-8596-0299E0343C92 Q33408536-BA066E51-5E36-45C2-964A-C395D63CE145 Q34034756-0F5EB7C8-8275-4ACF-8356-6D6CE736431D Q35223221-FC15676F-15D6-4932-87CD-8651A85FC8B8 Q36096741-B5D8CE0A-C9AD-40A4-A951-3E42841C6EF2 Q36273796-61D8C8A7-3814-4825-8D9D-C89FA025D405 Q36763814-7BE38E8F-0E19-4720-8742-450707EAB051 Q37155611-D193F39B-458A-48CC-BB5D-DDB822CC7845 Q38042256-5776353D-79C2-42E9-8119-24C6B7224644 Q38154186-6427BA71-470A-4D6B-9C9E-F38DAC61A938 Q38350045-F6A3BECC-3145-4968-ABAF-55FE861A6A75 Q47154720-2E813146-AA1A-4DC6-BF95-46E69B903164 Q52646693-5A4B2AFA-770C-4FF8-A3F2-97C0A96ADAE2 Q55228769-3AF9510C-BBE2-49EA-9EE5-08ADBE6FF858

P2860

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

http://www.wikidata.org/entity/Q37991128

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@en

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@nl

type

label

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@en

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@nl

prefLabel

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@en

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@nl

P1433

Q37991128-134427DB-EC59-4164-BE09-53C78F69050E

P1476

Q37991128-25C491FF-FA23-46A3-8CB9-0C68334C80A7

P2093

Q37991128-FE959E55-56E3-4205-8A04-4BC0182D4355

P2860

Q37991128-514275E1-48DB-4BA6-A9CA-64E6BEE5D91F

Q37991128-540DC8AF-9DF3-427F-A553-AE395DEA6B30

Q37991128-553EDBE4-1C7D-4187-ADEC-9DAE3BFF6667

Q37991128-650793EE-1F0A-418D-B273-4BFB3BEF7CF6

Q37991128-69FC892F-C6AB-48C5-9B3A-0B7D46CB4514

Q37991128-749C4C24-BCBC-412C-B52F-301F00A2930D

Q37991128-8427C930-F2C6-4D8A-84FB-D31E34EB0415

Q37991128-8ED3539D-6A84-4306-8310-0D45D81F7723

Q37991128-AA7DFB92-2423-4BF2-B287-C28EA6B45F42

Q37991128-ADD11EB5-0AAA-4D8C-A589-24841CECF03A

P304

Q37991128-8F2C9C69-B3EB-4913-90A2-3EE9B3B39EA4

P31

Q37991128-EB152CF7-5C21-4D08-9C39-64154543067E

P356

Q37991128-82AF3543-37D1-4672-94AB-070EB529410A

P407

Q37991128-8FE9B33B-17C8-4C98-8546-96A1A1D41D4D

P433

Q37991128-5C80F517-DA8E-49BC-9F0A-259089AA1972

P478

Q37991128-F6E70402-4746-4FFB-AF6B-7FBED94F458B

P577

Q37991128-8FC9598C-0DA8-4730-A065-D632C181171D

P698

Q37991128-DEB0D757-1E70-4468-921E-21C257C58657

P356

P1433

Annals of Pharmacotherapy

P1476

Brentuximab vedotin: a new age ...... naplastic large cell lymphoma.

@en

P2093

Stephanie S Minich

http://www.w3.org/2001/XMLSchema#string

P2860

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.

Anti-CD30 Antibodies for Hodgkin lymphoma.

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).

CD30: an important new target in hematologic malignancies.

CD30-targeted antibody therapy.

Brentuximab Vedotin (SGN-35).

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

P304

377-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1Q680

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22395252

http://www.w3.org/2001/XMLSchema#string